The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Real-world, long-term efficacy of CPX-351, and the impact of MRD, in patients with t-AML or AML-MRC
|
A retrospective analysis assessed the real-world efficacy of CPX-351 in 168 adult patients with ND t-AML (n = 47) or AML-MRC (n = 121) and evaluated the impact of MRD on long-term outcomes.1 Results from this trial were published in Blood Advances by Cluzeau et al.1 |
| Key learnings |
| The ORR, CR, and CRi rates were 60%, 53%, and 6%, respectively, and, after a median follow-up of 3 years, the median OS was 13.3 months. |
| The median OS for MRD− vs MRD+ patients was 20.4 months vs 12.9 months (p = 0.03). In multivariate analysis, MRD-positivity was associated with shorter OS (HR, 2.6; 95% CI, 1.2–5.5; p = 0.013). |
| Among patients who underwent allo-HSCT, there was a trend towards improved median OS in MRD− patients vs MRD+ patients (not reached vs 26.0 months; p = 0.06). |
| Results from this analysis confirm the efficacy of CPX-351 in real-world patients with ND t-AML and AML-MRC and highlight the prognostic impact of MRD-negativity in this patient population. |
Abbreviations: allo-HSCT, allogeneic hematopoietic stem cell transplantation; AML-MRC, acute myeloid leukemia with myelodysplasia-related changes; CI, confidence interval; CR, complete remission; CRi, CR with incomplete hematological recovery; HR, hazard ratio; MRD, measurable residual disease; ORR, overall response rate; OS, overall survival; t-AML, therapy-related acute myeloid leukemia.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
